XARELTO®: Chronic coronary artery disease and peripheral artery disease treatment

In CAD/PAD, dual pathway inhibition with the XARELTO® 2.5 mg vascular dose targets both clotting mechanisms at once2

XARELTO® 2.5 mg twice daily with aspirin (75 mg to 100 mg) once daily.

Graphic showing how XARELTO® targets 2 clotting mechanisms at once, platelet aggregation and thrombin generation.

The clinical significance of this mechanistic information has not been established.

*Patients with chronic coronary syndromes (chronic CAD) and in sinus rhythm.

CAD = coronary artery disease; DOAC = direct oral anticoagulant; ESC = European Society of Cardiology; PAD = peripheral artery disease.